The global biopharmaceutical landscape is currently dominated by Monoclonal Antibodies (mAbs). As highly specific proteins designed to bind to unique targets, mAbs have revolutionized the treatment of oncology, autoimmune diseases, and infectious pathologies. The market is projected to exceed USD 400 billion by 2030, driven by the increasing prevalence of chronic diseases and the emergence of biosimilars.
Industrial demand for high-quality monoclonal antibody production has shifted from small-batch laboratory synthesis to large-scale, cost-effective manufacturing. As a premier China OEM/ODM Monoclonal Antibodies supplier, we bridge the gap between innovation and accessibility.
Current trends in the mAb industry focus on Next-Generation Bioprocessing. This includes the move toward "Single-Use Technologies" to reduce contamination risks and "Continuous Manufacturing" to enhance yield. Global procurement teams are no longer just looking for a product; they are looking for reliable partners who can provide integrated solutions from cell line development to final packaging.
Worldwide enterprises are seeking Chinese factories that adhere to international GMP standards while offering the agility of OEM/ODM services. Our facility in Hangzhou meets these rigorous demands, ensuring every batch of monoclonal antibody products meets the highest purity and potency criteria.
Precision Cultivation: Single Use Bioreactor Systems
Monoclonal antibodies are integrated into various localized healthcare and industrial workflows:
Used in rapid test kits for high-sensitivity detection of viral antigens, such as Malaria and Chikungunya, providing immediate results in clinical settings.
Administered via prefilled syringes for chronic disease management, where stability and dosage precision are paramount.
Development of vaccines for rabbit hemorrhagic disease and other livestock-specific pathogens using recombinant protein technology.
End-to-End Packaging: Prefilled Syringe Solutions
Hangzhou Jeci Biochem Technology Co., Ltd. stands at the forefront of the Chinese biopharmaceutical industry. Our location in the Zhejiang high-tech corridor allows us access to top-tier talent and a world-class supply chain.
Our collaborative R&D team works deeply with new drug research institutes and multiple custom processing plants. We don't just supply products; we provide technical transfer, product registration, and factory quality management consulting.
For international clients, we offer a seamless bridge to the Chinese market and expert export services to India, Southeast Asia, South Korea, and Japan.
Our drugs and intermediates are widely used across multiple sectors:
We are equipped to assemble and produce larger quantities of intermediates using state-of-the-art batch processing and customization capabilities. Our infrastructure is designed to meet strict deadlines and volume requirements without compromising on biological integrity.
Hangzhou Jeci Biochem Technology Co., Ltd. is committed to the sales of active pharmaceutical ingredients, nutritional products, and food additives. Internationally, we maintain long-term trade relations and provide comprehensive market registration and sales channel expansion services for overseas companies entering China.
SJ medical
